Market research
CHMA Chiasma Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 238M
- P/E ratio
- Not available
- Analyst target
- 9.1
- Dividend yield
- 0.0%
- Beta
- 1.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US16706W1027
- Market cap
- 238M
- P/E ratio
- Not available
- Analyst target
- 9.1
- Dividend yield
- 0.0%
- Beta
- 1.26
About
About Chiasma Inc
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CHMA discussion.
5 years, 4 months ago
Chiasma, Inc is currently in a long term uptrend where the price is trading 10.2% above its 200 day moving average.
From a valuation standpoint, the stock is 89.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 144.0.
Chiasma, Inc's total revenue rose by inf% to $964K since the same quarter in the previous year.
Its net income has dropped by 64.4% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 112.0% to $-21M since the same quarter in the previous year.
Based on the above factors, Chiasma, Inc gets an overall score of 3/5.